Literature DB >> 18941194

IL-24 induces apoptosis of chronic lymphocytic leukemia B cells engaged into the cell cycle through dephosphorylation of STAT3 and stabilization of p53 expression.

Alexander Sainz-Perez1, Hélène Gary-Gouy, Françoise Gaudin, Ghyath Maarof, Anne Marfaing-Koka, Thierry de Revel, Ali Dalloul.   

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of long-lived monoclonal B cells mostly arrested at the G(0)/G(1) phase of the cell cycle. CLL cells strongly express intracellular melanoma differentiation-associated gene-7 (MDA7)/IL-24. However, adenovirus-delivered MDA7 was reported to be cytotoxic in several tumor cell lines. We report herein that rIL-24 alone had no effect; however, sequential incubation with rIL-2 and rIL-24 reduced thymidine incorporation by 50% and induced apoptosis of CLL cells in S and G(2)/M phases of the cell cycle, but not of normal adult blood or tonsil B cells. IL-24 stimulated STAT3 phosphorylation in IL-24R1-transfected cells but not in normal or CLL B cells. In contrast, IL-24 reversed the IL-2-induced phosphorylation of STAT3 in CLL, and this effect was neutralized by anti-IL-24 Ab. Phospho- (P)STAT3 inhibition induced by IL-24 was reversed by pervanadate, an inhibitor of tyrosine phosphatases. The addition of rIL-24 to IL-2-activated CLL B cells resulted in increases of transcription, protein synthesis. and phosphorylation of p53. The biological effects of IL-24 were reversed by the p53 inhibitor pifithrin-alpha and partly by the caspase inhibitor zvad. Troglitazone (a protein tyrosine phosphatase, PTP1B activator) phosphatase inhibited PSTAT3 and augmented p53 expression. PSTAT3 is a transcriptional repressor of p53, and therefore IL-24 induction of p53 secondary to PSTAT3 dephosphorylation may be sensed as a stress signal and promote apoptosis in cycling cells. This model explains why IL-24 can protect some resting/differentiated cells and be deleterious to proliferating cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18941194     DOI: 10.4049/jimmunol.181.9.6051

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

Review 1.  Immunomodulation in leukemia: cellular aspects of anti-leukemic properties.

Authors:  M Maleknia; A Valizadeh; S M S Pezeshki; N Saki
Journal:  Clin Transl Oncol       Date:  2019-05-24       Impact factor: 3.405

2.  A novel function of RNAs arising from the long terminal repeat of human endogenous retrovirus 9 in cell cycle arrest.

Authors:  Lai Xu; Abdel G Elkahloun; Fabio Candotti; Andrzej Grajkowski; Serge L Beaucage; Emanuel F Petricoin; Valerie Calvert; Hartmut Juhl; Frederick Mills; Karen Mason; Neal Shastri; Josh Chik; Cynthia Xu; Amy S Rosenberg
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

3.  Coactosin-like protein CLP/Cotl1 suppresses breast cancer growth through activation of IL-24/PERP and inhibition of non-canonical TGFβ signaling.

Authors:  L Xia; X Xiao; W L Liu; Y Song; T J J Liu; Y J Li; E Zacksenhaus; X J Hao; Y Ben-David
Journal:  Oncogene       Date:  2017-09-18       Impact factor: 9.867

4.  Melanoma differentiation associated gene-7/interleukin-24 potently induces apoptosis in human myeloid leukemia cells through a process regulated by endoplasmic reticulum stress.

Authors:  Mohamed Rahmani; Mandy Mayo; Rupesh Dash; Upneet Kaur Sokhi; Igor P Dmitriev; Devanand Sarkar; Paul Dent; David T Curiel; Paul B Fisher; Steven Grant
Journal:  Mol Pharmacol       Date:  2010-09-21       Impact factor: 4.436

5.  Adenovirus-mediated IL-24 confers radiosensitization to human lung adenocarcinoma in vitro and in vivo.

Authors:  Shi-Ying Zheng; Jin-Feng Ge; Jun Zhao; Dong Jiang; Fang Li
Journal:  Mol Biol Rep       Date:  2014-12-06       Impact factor: 2.316

6.  Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells.

Authors:  Raffaella Bosco; Marco Rabusin; Rebecca Voltan; Claudio Celeghini; Federica Corallini; Silvano Capitani; Paola Secchiero
Journal:  Invest New Drugs       Date:  2010-10-16       Impact factor: 3.850

7.  SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma.

Authors:  L-C Fan; C-W Shiau; W-T Tai; M-H Hung; P-Y Chu; F-S Hsieh; H Lin; H-C Yu; K-F Chen
Journal:  Oncogene       Date:  2015-01-26       Impact factor: 9.867

8.  Activation of p53 promotes renal injury in acute aristolochic acid nephropathy.

Authors:  Li Zhou; Ping Fu; Xiao R Huang; Fei Liu; Kar Neng Lai; Hui Y Lan
Journal:  J Am Soc Nephrol       Date:  2009-11-05       Impact factor: 10.121

9.  Expression and regulation of CacyBP/SIP in chronic lymphocytic leukemia cell balances of cell proliferation with apoptosis.

Authors:  Chunling Fu; Yan Wan; Hengliang Shi; Yanqing Gong; Qingyun Wu; Yao Yao; Mingshan Niu; Zhenyu Li; Kailin Xu
Journal:  J Cancer Res Clin Oncol       Date:  2015-11-25       Impact factor: 4.553

10.  Protein tyrosine phosphatase-1B modulates pancreatic β-cell mass.

Authors:  Rebeca Fernandez-Ruiz; Elaine Vieira; Pablo M Garcia-Roves; Ramon Gomis
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.